These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3687342)

  • 1. L1210 leukemia regression in non-immunosuppressed mice with therapeutic transfer of immune spleen cells--therapeutic adoptive transfer against L1210 leukemia.
    Kawashima K; Nagura E; Nagase F; Kumazawa T; Nakashima I; Yamada K
    Nihon Ketsueki Gakkai Zasshi; 1987 Sep; 50(6):1174-82. PubMed ID: 3687342
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive immunotherapy in BALB-c times DBA-2 Cr F1 mice bearing an immunogenic subline of L1210 leukemia.
    Nicolin A; Canti G; Goldin A
    Cancer Res; 1974 Nov; 34(11):3044-8. PubMed ID: 4424774
    [No Abstract]   [Full Text] [Related]  

  • 3. Adoptive immunotherapy against a local or widespread tumor of a highly malignant and poorly immunogenic mouse leukemia L1210.
    Naguma E; Kawashima K; Nagase F; Nakashima I; Ohno R; Yamada K
    Nihon Ketsueki Gakkai Zasshi; 1986 Sep; 49(6):1212-21. PubMed ID: 3492848
    [No Abstract]   [Full Text] [Related]  

  • 4. Enhanced induction of immune resistance by concanavalin A-bound L1210 vaccine and an immunopotentiator prepared from Coriolus versicolor.
    Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y
    Cancer Res; 1977 Dec; 37(12):4416-9. PubMed ID: 922733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.
    Kataoka T; Kobayashi H; Sakurai Y
    Cancer Res; 1978 May; 38(5):1202-7. PubMed ID: 639053
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
    Ujiie T
    Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of antitumor T-cells in tumor-bearing mice treated with tumor vaccine and 6-mercaptopurine.
    Kataoka T; Oh-hashi F
    Cancer Res; 1985 Jul; 45(7):2962-6. PubMed ID: 3873988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A.
    Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y
    Cancer Res; 1977 Apr; 37(4):964-8. PubMed ID: 403001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy and chemo-immunotherapy in murine L-1210 leukemia and its influence on the kinetics of leukemic proliferation.
    Rytwiński K
    Arch Immunol Ther Exp (Warsz); 1979; 27(6):819-27. PubMed ID: 549532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
    Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
    Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy between low-dose chemotherapy and immunotherapy in mouse L1210 leukemia.
    Relyveld EH; Bizzini B; Ophir R; Ben-Efraim S
    Cancer Treat Rep; 1987 Mar; 71(3):241-6. PubMed ID: 3102055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved host defense against L1210 leukemia by deprivation of dietary phenylalanine.
    Pine MJ
    Nutr Cancer; 1981; 3(2):94-102. PubMed ID: 7346795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical and biological adjuvants capable of potentiating tumor cell vaccine.
    Chirigos MA; Stylos WA; Schultz RM; Fullen JR
    Cancer Res; 1978 Apr; 38(4):1085-91. PubMed ID: 416906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceleration of allogeneic antitumor immunity with immune RNA in vitro and T-cell suppression by L1210 tumor bearer spleen cells.
    Miura T; Maekawa T; Kurashige S; Mitsuhashi S
    Cancer Res; 1981 Feb; 41(2):383-98. PubMed ID: 6160907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of cytotoxic T-lymphocytes in the antitumor activity of spergualin against L1210 cells.
    Umezawa H; Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T
    Cancer Res; 1987 Jun; 47(12):3062-5. PubMed ID: 3495325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
    Rahman SM; Kawashima K; Nakashima I; Nagase F
    Cancer Res; 1988 Nov; 48(22):6450-4. PubMed ID: 3263189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H
    Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of a unique tumor-associated surface antigen on L1210 leukemia cells recognized by semisyngeneic antisera.
    Yokochi T; Kawashima K; Nakashima I; Nagase F; Isobe K; Nagura E; Yamada K; Miyadai T; Kimura Y
    Cancer Res; 1987 Feb; 47(4):1006-9. PubMed ID: 3542198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of a new interferon inducer and leukocyte interferon for a significant enhancement of the immunocytotherapy of leukemia in mice].
    Madzhidov AV; Poverennyĭ AM; Popov GA; Fuks BB
    Biull Eksp Biol Med; 1983 Jan; 95(1):63-5. PubMed ID: 6830962
    [No Abstract]   [Full Text] [Related]  

  • 20. Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654).
    Skórski T; Kawalec M
    Bone Marrow Transplant; 1987 Dec; 2(4):435-40. PubMed ID: 3332191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.